Next report date
Report period
H1 2024
EPS estimate
−0.08HKD
Revenue estimate
157.09 MHKD
−2.74HKD
−103.88 MHKD
256.74 MHKD
12.85 M
About SHANGHAI HEARTCARE MEDICAL TECHNOLO
Sector
Industry
CEO
Guo Hui Wang
Website
Headquarters
Shanghai
Employees (FY)
368
Founded
2016
ISIN
CNE100004MN5
FIGI
BBG01231S8S0
Shanghai Heartcare Medical Technology Corp. Ltd. engages in the research, development, manufacture, and sale of neuro-interventional medical devices. Its objective is to redefine the therapeutic and preventive paradigm of stroke. The company was founded by Guo Hui Wang, Kui Ding, and Jia Qi Hong on June 16, 2016 and is headquartered in Shanghai, China.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 6609 is 17.90 HKD — it has decreased by 3.87% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange SHANGHAI HEARTCARE MEDICAL TECHNOLO stocks are traded under the ticker 6609.
SHANGHAI HEARTCARE MEDICAL TECHNOLO is going to release the next earnings report on Aug 28, 2024. Keep track of upcoming events with our Earnings Calendar.
6609 stock is 4.14% volatile and has beta coefficient of 0.56. Check out the list of the most volatile stocks — is SHANGHAI HEARTCARE MEDICAL TECHNOLO there?
6609 earnings for the last quarter are −1.53 HKD per share, whereas the estimation was −1.30 HKD resulting in a −18.33% surprise. The estimated earnings for the next quarter are −1.14 HKD per share. See more details about SHANGHAI HEARTCARE MEDICAL TECHNOLO earnings.
SHANGHAI HEARTCARE MEDICAL TECHNOLO revenue for the last quarter amounts to 118.43 M HKD despite the estimated figure of 115.87 M HKD. In the next quarter revenue is expected to reach 132.67 M HKD.
Yes, you can track SHANGHAI HEARTCARE MEDICAL TECHNOLO financials in yearly and quarterly reports right on TradingView.
6609 stock has risen by 11.87% compared to the previous week, the month change is a 4.38% fall, over the last year SHANGHAI HEARTCARE MEDICAL TECHNOLO has showed a 53.75% decrease.
6609 net income for the last quarter is −42.86 M HKD, while the quarter before that showed −61.45 M HKD of net income which accounts for 30.25% change. Track more SHANGHAI HEARTCARE MEDICAL TECHNOLO financial stats to get the full picture.
Today SHANGHAI HEARTCARE MEDICAL TECHNOLO has the market capitalization of 677.81 M, it has decreased by 2.94% over the last week.
No, 6609 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 6609 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SHANGHAI HEARTCARE MEDICAL TECHNOLO stock right from TradingView charts — choose your broker and connect to your account.
As of May 1, 2024, the company has 368.00 employees. See our rating of the largest employees — is SHANGHAI HEARTCARE MEDICAL TECHNOLO on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SHANGHAI HEARTCARE MEDICAL TECHNOLO technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SHANGHAI HEARTCARE MEDICAL TECHNOLO stock shows the sell signal. See more of SHANGHAI HEARTCARE MEDICAL TECHNOLO technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on SHANGHAI HEARTCARE MEDICAL TECHNOLO future price: according to them, 6609 price has a max estimate of 29.80 HKD and a min estimate of 28.91 HKD. Read a more detailed SHANGHAI HEARTCARE MEDICAL TECHNOLO forecast: see what analysts think of SHANGHAI HEARTCARE MEDICAL TECHNOLO and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SHANGHAI HEARTCARE MEDICAL TECHNOLO EBITDA is −93.21 M HKD, and current EBITDA margin is −40.71%. See more stats in SHANGHAI HEARTCARE MEDICAL TECHNOLO financial statements.